Companies › ProMis Neurosciences
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PMN310 Humanized IgG1 monoclonal antibody | – | Phase 1 | Alzheimer Disease, Early Onset | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06750432 | PMN310 | Phase 1 | Alzheimer Disease, Early Onset | Neurology | Dec 2026 |
Cash and short-term investments of $53m on 2026-06-30; operating cash outflow about $46m a year; runway about 14 months at that burn, to Aug 2027
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.